The new in anticoagulation: factor XI inhibitors

Overview of attention for article published in European Heart Journal Supplements: Journal of the European Society of Cardiology, April 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#7 of 578)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter: 169 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 178 X posts from 169 X users, with an upper bound of 322,126 followers.

@BerryTartlet Oh yes. Asundexian is probably the largest Phase 3 program. Their AFib trial just ‘failed’ unfortunately, but there’s other Phase 3s underway. MK2060- in kidney disease. Etc. https://t.co/ItRFsG1Lpk

25 Nov 2023

Reply Repost Favourite

RT @gabi_puchepalao: 🔥INHIBIDORES DEL FACTOR XI COAGULACIÓN(FXI)🔥 La inhibición de la vía de contacto (1ª fase vía intrínseca coagulación)…

19 Oct 2023

Reply Repost Favourite

RT @sefh_: Los inhibidores del factor XI podrían prevenir la trombosis con un mínimo efecto sobre la hemostasia por lo que tendrían un bajo…

19 Jun 2023

Reply Repost Favourite

RT @LeonardoSotoMu: Lo nuevo: inhibidores del factor XI https://t.co/QsGX1mNyLH

07 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 174 additional X posts.